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ABSTRACT (250 words): Mutations in WNK1 and WNK4 cause monogenetically 
inherited hypertension, the Gordon syndrome. The coded proteins contribute to the 
regulation of renal salt homeostasis, and thereby to the determination of blood pressure 
(BP). We have conducted a polymorphism screening in WNK1 and WNK4 conserved 
non-coding regions and identified an undescribed polymorphic AluYb8 insertion in 
WNK1 intron 10. Screening in primates revealed that this Alu-insertion has probably 
occurred in human lineage. Genotyping in 22 populations from Europe, Asia and Africa 
(854 individuals) indicated an expansion of the WNK1 AluYb8 bearing chromosomes out-
of-Africa. The allele frequency of this Alu-insertion in Sub-Saharan Africa was ~3.3 
times lower than in other studied populations (4.8% versus 15.8%; P=9.7x10
-9
). The 
carrier-status of the WNK1 AluYb8 insertion was explored for the association with 
cardiovascular traits and the effect on gene expression profile. The Alu-insertion was 
significantly associated with SBP and DBP (P=0.0126 and P=0.0304, respectively; 
HYPEST study, n=1211). Gender-specific analysis revealed a more pronounced effect 
among women (SBP: P=0.013; DBP: P=0.006). In both, essential hypertension (17.7%) 
and CAD (17.23%) patients the allele frequency of the AluYb8 insertion was higher 
compared to controls (14.51% and 15.32%, respectively). In leucocytes, the expression of 
WNK1 splice-form excluding exon 11 was reduced in AluYb8 carriers compared to 
wildtype subjects (P≤0.002). Interestingly, the expression of the full-length WNK1 
transcript was up-regulated among AluYb8 homozygous carriers (P=0.036) and down-
regulated among heterozgotes (P=0.006). In summary, the identified WNK1 AluYb8 
insertion may have a functional effect on WNK1 transcription profile and consequently on 
human BP determination. 
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Introduction 
Essential hypertension is a complex disease promoted by an unfavorable combination of 
a person’s life-style and heritable factors. It is a significant health risk leading to other 
cardiovascular and renal diseases. Genetic studies of monogenic, Mendelian forms of 
hypo- and hypertension have identified ~20 rare mutations in blood pressure regulating 
genes with a strong effect on the phenotype (Lifton, et al., 2001; Vehaskari, 2007). 
Although these rare mutations do not explain blood pressure variation in general 
population, the identified genes are promising targets for functional, physiological and 
genetic studies of essential hypertension (Ji, et al., 2008; REF).  
Serine/threonine protein kinase family members WNK1 and WNK4 (With No K (lysine); 
Xu, et al., 2000) are involved in the development of a Mendelian form of hypertension, 
pseudohypoaldosteronism type II or the Gordon syndrome (Wilson, et al., 2001; Wilson, 
et al., 2003). The syndrome is caused either by a large deletion (two identified variants: 
22 kb and 42 kb) in the first intron of WNK1 or by a non-synonymous substitution in 
WNK4 (four described mutations). Although WNK1 and WNK4 are expressed in multiple 
tissues, their major role is to regulate the transport of sodium and potassium ions in distal 
convoluted tubule and cortical collecting duct of nephrons, and thereby to contribute to 
blood pressure determination (Verissimo and Jordan, 2001; Wilson, et al., 2001). The 
human WNK4 gene (19 exons) spans ~16 kb on chromosome 17q21.31. The human 
WNK1 gene (28 exons+1 alternative exon) covers ~160 kb on chromosome 12p13 and 
codes for multiple transcripts initiated by alternative promoters (Wilson, et al., 2001; Xu 
Q, et al., 2002; Delaloy, et al., 2003;). Two major WNK1 isoforms have been described, 
a long isoform with complete kinase domain (L-WNK1) and a short kidney-specific 
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isoform, which is kinase-deficient (KS-WNK1) (Xu, Q et al., 2002). Although multiple 
alternative splice-forms of WNK1 have been identified, the function of individual 
transcripts is yet to be determined. In addition to the identification of rare variants in 
WNK1 and WNK4 responsible for the Gordon syndrome, common single nucleotide 
polymorphisms (SNPs) in these genes have been associated with blood pressure variation 
and susceptibility to hypertension in general population among adults as well as children 
(Kokubo, et al., 2004; Newhouse, et al., 2009; Newhouse, et al., 2005; Osada, et al., 
2009; Tobin, et al., 2005; Tobin, et al., 2008). SNPs in WNK1 also affect the response of 
thiazide diuretics treatment on patient’s blood pressure (Turner, et al., 2005).  
While monogenic diseases are usually caused by rare variants located in the coding 
sequence of a gene, common diseases are rather considered to result from genetic 
variation in gene regulatory elements altering the expressional profile of the locus 
(Pastinen and Hudson, 2004; Visel, et al., 2009). As gene regulatory elements tend to 
map within evolutionarily conserved segments of the genome (Elgar and Vavouri, 2008; 
Hardison, 2000), these regions have a potential to harbor polymorphisms affecting 
common traits.  
The aim of the current study was to screen the evolutionarily conserved non-coding 
regions of WNK1 and WNK4 to identify novel polymorphisms potentially affecting blood 
pressure in general population. Mutation screening resulted in the identification of a 
novel human-specific polymorphic AluYb8 insertion in WNK1 intron 10. This Alu-
insertion was targeted to further evolutionary and population genetic analysis, as well as 
was also explored for association with blood pressure and its effect on the transcriptional 
profile of the WNK1 gene in leucocytes. 
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Materials and Methods 
In silico analysis of conserved non-coding regions in WNK1 and WNK4 
Conserved Non-coding Regions (CNRs) in WNK1 and WNK4 were screened using the 
web-based VISTA software (http://genome.lbl.gov/vista/index.shtml) with the proposed 
default parameters (cutoff criteria: 100 bp sliding window; sequence identity 70%; 
comparison with rat and mouse). The analyzed loci spanned from 10 kb upstream to 10 
kb downstream of WNK1 (12p13.3; coordinates 722,486-900,879, NCBI Build 36.1, 
hg18) and WNK4 (17q21.31; coordinates 38,176,222- 38,212,587, NCBI Build 36.1, 
hg18). All VISTA regions that had any overlap with annotated genes track at UCSC 
Genome Browser (http://genome.ucsc.edu/) were excluded as potential coding regions. 
Polymorphism discovery was targeted to CNRs with sequence identity >70% between 
human and both rodents, length of the region 50-300 bp, and location >200bp from the 
nearest exon (Supplementary Table S1). 
 
Screening for novel polymorphisms in WNK1 and WNK4 conserved non-coding 
regions 
In total 40 (n=29 in WNK1; n=11 in WNK4) CNRs were selected for polymorphism 
screening, which was conducted either by Denaturing Gradient Gel Electrophoresis 
(DGGE; INGENYphorU-2x2 system, Ingeny International BV, Goes, The Netherlands) 
and/or Denaturing High-Performance Liquid Chromatography method (DHPLC; Wave 
Technologies Inc. USA). In the design of the DGGE and DHPLC assays and in 
establishing the experimental conditions, the manufacturers’ recommendations were 
followed. Details of the assays are given in Supplementary Text S1. The design of both 
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DGGE and DHPLC assays was unsuccessful for 7 CNRs in WNK1 and 2 CNR in WNK4 
due to failure in primer design or a negative result in the genome test (Supplementary 
Table S1). The rest of the 31 selected CNRs were screened for polymorphisms either by 
DHPLC (7 regions in WNK1; 5 in WNK4), by DGGE (7 in WNK1; 1 in WNK4) or by 
both assays (8 in WNK1; 3 in WNK4; Supplementary Table S1). 
The average length of the analyzed CNR segments was 145 bp (range: 68-291 bp) and 
PCR fragments was 358 bp (range: 245-487 bp). Genomic DNAs of cardiovascular 
disease patients from two Eastern European studies (n=22 from HYPEST; n=24 from 
CADCZ; detailed description below) were targeted to polymorphism screening by DGGE 
(individual DNAs) and/or DHPLC (pools of DNA from three patients). PCR products 
exhibiting evidence for the presence of a polymorphism were sequenced at least twice on 
both forward and reverse orientations.  Polymorphisms were identified using BioEdit 
Sequence Alignment Editor (Hall T., Department of Microbiology, North Carolina State 
University). 
 
Genotyping of the WNK1 AluYb8 in human populations  
For large scale genotyping of WNK1 AluYb8 in humans PCR followed by standard 
agarose gel (3% in 0.5X TBE buffer) electrophoresis was used. The primer design 
(WNK1_Alu_F: 5`-GGGTAACCAACCCTTGAAGTAGG-3`; WNK1_Alu_R: 5`-
GGGTACTTCTCAAGTGATTAGGAGGA-3`) was carried out using the web-based 
program Primer3 (Rozen and Skaletsky, 2000). The distribution of the WNK1 AluYb8 
insertion was studied in six European (Estonians, n=50; Czech, n=50; CEPH, n=30; the 
Basque, n=50; Catalans, n=41; Spanish Gypsies, n=50), four Asian (Koreans, n=43; 
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Chinese Han, n=25; Tatars, n=47; Bashkir, n=47) and eight African populations 
(Tunisians, n=48; Algerians, n=48; Moroccans, n=84; Mandenkalu, n=24; Saharawi, 
n=50; Gabon Bantus, n=50; Gabon Pygmies, n=50; Tanzanians, n=17). 
 
Conservation of the WNK1 AluYb8 insertion in primates 
The presence of the WNK1 AluYb8 insertion was ascertained for a gorilla (Gorilla 
gorilla; primary cell line AG05251B), for an orangutan (Pongo pygmaeus; primary cell 
line AG12256) and for eleven western chimpanzees (Pan troglodytes verus) using 
identical PCR setup as in human genotyping. DNA sample of one chimpanzee originates 
from a wild-born male specimen (Pino) from Tallinn Zoo, Estonia. Ten samples of wild 
caught and unrelated animals (Annaclara, Frits, Hilko, Louise, Marco, Oscar, Regina, 
Socrates, Sonja and Yoran) are from the collection stored at the Max Planck Institute for 
Evolutionary Anthropology, Leipzig, Germany and were kindly shared by Dr. Svante 
Pääbo. This sample collection is described in detail in Becquet, et al., 2007 and Ptak, et 
al., 2004. 
Ancestral sequence of the targeted genomic region (WNK1 exon10-intron10-exon11) was 
assessed by the comparative sequencing of the genomic DNA from WNK1 AluYb8 
insertion non-carrying (-/-) and carrying (Alu/Alu) human homozygotes as well as from a 
chimpanzee (Pino). Sequencing primers are listed in Supplementary Table S3. PCR 
cycling conditions, product purification and sequencing have been described elsewhere 
(Hallast, et al., 2005). Sequences were aligned using web-based global alignment 
program ClustalW2 (http://www.ebi.ac.uk/Tools/clustalw2/).  
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Subjects for association studies with cardiovascular traits  
Two Eastern-European sample collections, HYPEST (HYPertension in ESTonia) and 
CADCZ (Coronary Artery Disease in Czech) were used to conduct association analysis 
of the WNK1 AluYb8 insertion with blood pressure and cardiovascular disease (Table 1). 
These sample collections have been recruited to target the genetic-epidemiological 
component of cardiovascular disease in Estonian and Czech populations, respectively. 
HYPEST subjects were recruited across Estonia during 2004-2007 (1823 individuals, age 
range 18-85 years) with the aim to evaluate risk factors for essential hypertension and 
related cardiovascular disease. Details of the recruitment are given in Supplementary 
Text S1. The CADCZ study subjects (n=877; n=296 coronary artery disease patients, 
n=581 controls) were recruited by the Cardiology Department of the 2
nd
 Clinic of Internal 
Medicine, Faculty Hospital Královské Vinohrady in Prague and Czech heath clinics in 
years 1998-2000 (Janosikova, et al., 2003).  
For the HYPEST subjects resting blood pressure was measured by trained clinicians 
during recruitment. Blood pressure (BP) measurements per subject were obtained using a 
standard mercury column sphygmomanometer and size-adjusted cuffs. All HYPEST 
individuals possessed a documented history of multiple systolic (SBP) and diastolic 
(DBP) blood pressure readings (on average 4.31 readings per individual, range 2–29) 
during mean 3.17 years (range 1–17 years). For association analysis with SBP and DBP 
we used the median across the longitudinal BP readings, and we excluded subjects 
receiving antihypertensive medication and BMI > 36. Thus, from among the genotyped 
HYPEST subjects (n=1747), 1211 HYPEST individuals (803 women, 408 men) qualified 
for the association study with BP (Table 1). In the case-control analysis the subjects with 
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essential hypertension (n=673) were defined as individuals under antihypertensive 
treatment or untreated individuals with SBP≥160 and/or DBP≥100; and controls (n=601) 
as individuals with SBP≤140 and DBP≤90.  
Coronary artery disease (CAD) in CADCZ study was diagnosed according to WHO 
criteria, and one or more large stenosis of a major coronary vessel was confirmed by 
coronarography in all patients. Carotid wall intima media thickness (IMT) and the 
presence of carotid plaque, recorded in the CADCZ subjects were determined as 
described previously (Janosikova, et al., 2003). The CADCZ controls had no personal 
history of CAD, essential hypertension, MI, peripheral arterial disease, or stroke, and had 
never been prescribed any related medications. 
 
RNA extraction and cDNA synthesis 
EDTA-blood (9 ml) was collected from nine female subjects selected based on their 
alternative genotypes: three heterozygotes and three homozygotes for the WNK1 AluYb8 
insertion; and three subjects with wild-type sequence. Total RNA from leucocytes was 
extracted using LeukoLOCK™ Total RNA Isolation System (Ambion Inc, Austin, Texas, 
USA) including an optional TURBO™ DNase treatment to degrade the genomic DNA. 
Quantity and quality of extracted RNA was assessed with NanoDrop® ND-1000 UV-Vis 
Spectrophotometer (NanoDrop Technologies, LLC, Wilmington, Delaware, USA). 
RNA was reverse transcribed using SuperScript™ III First-Strand Synthesis SuperMix 
for qRT-PCR (Life Technologies Corporation, Carlsbad, California, USA) according to 
the manufacturer’s instructions (details in Supplementary Text S1). 
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Quantification of WNK1 transcripts by real-time PCR 
Relative expression analysis of three WNK1 splice-forms (ex+11+12, ex–11+12 and ex–
11–12; Figure 3A) was performed with real-time PCR. Primer-probe mix of the WNK1 
transcript including exon 11 (ex+11+12; Hs01018312_m1, amplicon size 78bp) and 
selected reference gene HPRT1 (Human HPRT1 (HGPRT) Endogenous Control (VIC / 
MGB Probe, Primer Limited, amplicon size 100 bp)) were purchased from Applied 
Biosystems, Inc. Primers and probes for the WNK1 transcripts lacking exon 11 (ex–
11+12) and both exons 11 & 12 (ex–11–12) were designed using Primer Express version 
3.0 (Applied Biosystems Inc, Foster City, CA, USA). Oligonucleotide sequences are 
given in Supplementary Table S3. 
The real-time RT-PCRs were performed using Applied Biosystems 7900HT Fast Real-
time PCR system in 96 micro-well plates. Target region and endogenous control were 
amplified in the same well. The experimental conditions for the real-time PCR are given 
in detail in Supplementary Text S1. In total six replicate analyses of each of the nine 
extracted RNA samples were conducted: two independently synthesized cDNAs were 
assayed by RT-PCR reactions in triplicate. 
 
Statistical analysis  
Statistical differences in allele frequencies between populations were calculated using the 
web-based Fisher´s Exact Test calculator (http://www.langsrud.com/fisher.htm). The 
significance of the associations between the WNK1 AluYb8 insertion and blood pressure 
(systolic blood pressure, SBP; diastolic blood pressure, DBP) was tested using linear 
regression (additive genetic model) with age and gender as covariates. Additive genetic 
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model assumes a trend per copy of the minor allele to contribute to the trait or disease 
susceptibility on genotype categories. Association with the diagnosis of cardiovascular 
disease (essential hypertension; coronary artery disease, CAD) was assessed by Cochran-
Armitage trend test. Association testes were implemented in the PLINK software, ver. 
1.04 (http://pngu.mgh.harvard.edu/~purcell/plink/).  
Normalized expression values of target regions were calculated using Microsoft
®
 Excel
®
-
based software Q-Gene (Muller, et al., 2002). Q-Gene calculates the normalized 
expression values of the target gene based on the Ct values and the reaction efficiencies 
of the target and the reference gene (here HPRT). For every study subject six replicate 
values of relative expression per each alternative WNK1 splice-form (ex+11+12, ex–
11+12 and ex–11–12) was calculated. As each of the genotypes (Alu/Alu, Alu/–; –/–) was 
represented by three individuals, in total 18 data-points were collected per transcript 
within a genotype group. The most outlier Ct value within the respective genotype group 
was excluded from the statistical testing. Differences of normalized expression values 
between alternative genotype groups were estimated by Wilcoxon rank sum test 
implemented in R, ver. 2.7.2 (R Development Core Team 2008, http://www.r-
project.org/). For all tests p-value <0.05 was considered as statistically significant.  
 
 
Results 
Polymorphism screening in WNK1 and WNK4 conserved non-coding regions 
DHPLC and/or DGGE assays were designed for screening novel polymorphisms in 
conserved non-coding regions (CNRs) of the WNK1 (29 targeted CNRs based on criteria 
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outlined in Materials and Methods) and the WNK4 (11 CNRs) genes (Supplementary 
Table S1). Based on the in silico quality control criteria for assay design, nine regions 
were excluded from the wet-lab analysis. Finally, 31 CNRs entered mutation detection in 
cardiovascular disease patients (HYPEST, 22 hypertensives; CADCZ, 24 CAD patients).  
Among the screened 31 CNRs, one single nucleotide polymorphism (SNP) was identified 
in the WNK4 and six SNPs in the WNK1 gene (Supplementary Table S2). All but one 
(rs36052085) of the detected SNPs were rare (minor allele frequency <10%), including 
three singletons (two novel). The functional effect of these SNPs was addressed neither 
by association studies due to large sample size requirements nor by gene expression 
analysis due to unavailability of minor allele homozygotes.  
In addition, in one of the WNK1 CNRs, a novel unreported common indel (~ 300 bp) was 
detected (Supplementary Table S2). Sequence analysis of this variant revealed a 
polymorphic insertion of an AluYb8 element (288 bp without flanking T nucleotides) into 
a poly-T tract within WNK1 intron 10 (Figure 1, Supplementary Figure S1). This Alu-
insertion was targeted to further evolutionary and population genetic analysis as well as 
was explored for the association with cardiovascular disease and the effect on the gene 
expression profile. 
 
 
Alu distribution in human populations 
The WNK1 AluYb8 insertion was genotyped in 22 populations from Europe, Asia and 
Africa (Supplementary Table S4). Frequency of the AluYb8 insertion in human 
populations differed based on their geographic affiliation (Table 2). The proportion of 
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WNK1 AluYb8 carriers in Sub-Saharan Africa was significantly lower (average allele 
frequency 4.8%; range 2.1–7.0%) compared to North-African (mean 16.4%, range 10.4–
25.0%; Fisher`s Exact Test, P=2.2x10
-6
), European (mean 15.1%, range 12.0–16.5%; 
P=8.7x10
-9
) and Asian (mean 15.9%, range 11.6%–22%; P=9.4x10-6). On average, the 
allele frequency of the WNK1 AluYb8 in Sub-Saharan Africa was ~3.3 times lower than 
in other studied populations (P=9.7x10
-9
). 
 
Alu insertion in primates and conservation around insertion site 
The analysis of the WNK1 intron 10 in eleven chimpanzees, one gorilla and one 
orangutan revealed that the WNK1 AluYb8 insertion has most probably occurred in 
human lineage. No AluYb8 insertion was detected in the WNK1 intron 10 of the studied 
primate genomes (Figure 1). Comparative sequencing of the WNK1 genomic fragment 
(exon10/ intron10/ exon11) amplified from a chimpanzee and from human wildtype as 
well as AluYb8 insertion carrying chromosomes revealed high conservation of intron 10 
(Supplementary Figure S1). The substitution divergence between human wildtype and 
chimpanzee WNK1 was 0%, 0.2% and 1.1% for exon 10 (150 bp), exon 11 (459 bp) and 
intron 10 (1211 bp), respectively.  
 
Association studies of the WNK1 AluYb8 insertion and cardiovascular traits 
Associations of the WNK1 AluYb8 insertion with systolic (SBP) and diastolic (DBP) 
blood pressure were tested by linear regression under additive genetic model (Table 3, 
Figure 2). In HYPEST study subjects (n=1211), the AluYb8 insertion was associated 
with significantly higher SBP (P=0.0126; beta=2.23) and DBP (P=0.0304; beta=1.22). 
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Gender-specific analysis revealed that the effect of the AluYb8 insertion on blood 
pressure is more pronounced in women (SBP: P=0.013, beta=2.72; DBP: P=0.006, beta= 
1.84), while no significant association was detected in men (Table 3). AluYb8-carrying 
homozygote HYPEST women had an average 4.5 mmHg higher median SBP and 3.5 
mmHg higher median DBP compared to wildtype homozygotes (Figure 2). Association 
of the WNK1 AluYb8 insertion with cardiovascular disease was studied in two Eastern 
European study samples: essential hypertension (HYPEST, Estonia; cases n=673/ 
controls n=601) and coronary artery disease, CAD (CADCZ, Czech; cases n=296/ 
controls n=581). Significant association was detected with clinically diagnosed essential 
hypertension (Cochran-Armitage trend test, P=0.029) and the association was stronger 
with female hypertension (P=0.016; Table 4). Although association testing with CAD 
did not reach statistically significant P-values, the differences in allele frequencies 
between cases and controls were consistent with the results for essential hypertension 
(Table 4). In hypertensives, the frequency of the AluYb8 insertion (17.7%) was >3 % 
higher compared to normotensives (14.51%). In CAD patients (17.23%) the difference 
from control group (15.32%) was ~ 2%. In both studies, the frequency of the AluYb8 
insertion in female patients was ~19% compared to <15% in female controls. 
 
The impact of the AluYb8 insertion on the expression profile of WNK1 in leukocytes 
In order to explore the functional effect of the AluYb8 insertion on the expression profile 
of WNK1, we quantified the gene transcripts in RNA extracted from the leukocytes of 
nine women with alternative genotypes. The study subjects included three individuals 
heterozygous and three homozygous for the AluYb8 insertion, as well as three wildtype 
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genotype carriers. The expression of three WNK1 splice-forms was addressed using 
relative quantification method based on real-time RT-PCR assays. The studied splice-
forms differed by alternative inclusion/exclusion of exon 11 and exon 12 (Figure 3A). 
Compared to the subjects with the wild-type genotype, the heterozygous AluYb8 carriers 
had significantly lower expression of all three splice-forms (Wilcoxon rank sum test; 
ex+11+12: P=0.006; ex–11+12: P=6.78x10-7; ex–11–12: P=0.005; Figure 3B). 
Consistently, homozygous AluYb8 carriers showed lower expression level of splice forms 
ex–11+12 (P=0.002) and ex–11–12 (P=0.182; Figure 3C). However, the expression of 
the full-length WNK1 transcript, which includes both exon 11 and 12 (ex+11+12) was up-
regulated among AluYb8 homozygous carriers (P=0.036). We conclude that the carrier-
status of the AluYb8 insertion may have an impact on the profile in WNK1 transcript in 
leukocytes. 
 
Discussion 
We targeted conserved non-coding regions in hypertension candidate genes WNK1 and 
WNK4 to polymorphism screening in order to identify functional variants potentially 
contributing to blood pressure determination. We identified a novel human-specific 
polymorphic AluYb8 insertion in WNK1 intron 10. 
The AluYb8 insertion belongs to a young Alu subfamily represented with ~2200 copies in 
the human genome compared to only nine insertions detected in chimpanzee (Gibbons, et 
al., 2004). Consistently, we were unable to detect the studied WNK1 AluYb8 insertion in 
chimpanzee, gorilla and orangutan (Figure 1). As AluYb8 elements are relatively mobile 
Alu-repeats, they represent together with AluYa5 subfamily ~58% of the polymorphic 
Polymorphic AluYb8 in WNK1  Putku et al 
 17 
Alu-s in the human genome (Bennett, et al., 2008). The increased carrier frequency of 
WNK1 AluYb8 insertion out of Africa is consistent with recent studies showing that the 
allele frequencies of polymorphic Alu-insertions tend to be lowest in Sub-Saharan 
populations (Table 2; (Watkins, et al., 2001 and 2003). In Africa, the fraction of carriers 
of polymorphic Alu-s increase with sharp cline in the north of Sahara compared to the 
populations living south of the desert (Comas, et al., 2000).  
Our study identified a significant association between WNK1 AluYb8 insertion and blood 
pressure in HYPEST sample (P<0.05) and suggested a potential functional effect of this 
Alu-insertion on the expressional profile of the WNK1 gene in leukocytes. In clinically 
diagnosed essential hypertension patients the allele frequency of the AluYb8 insertion 
(17.7%) was significantly (p<0.05) higher compared to normotensive controls (14.51%; 
Table 4). Consistently, a non-significant trend for association was observed with 
coronary artery disease (CAD) (cases 17.23%, controls 15.32%; Table 4) in CADCZ 
study. However, the association testing with CAD was limited by an insufficient sample 
size.  
In the current study the WNK1 AluYb8 insertion was associated with blood pressure only 
among women (Table 3). Consistently, it showed increased frequency among female, but 
not among male cardiovascular disease (essential hypertension, HYPEST study; CAD, 
CADCZ study) patients compared to healthy controls (Table 4). Similar gender-specific 
effects have been reported for the polymorphic Alu-insertion (rs4646994) located in 
intron 16 of the ACE (angiotensin converting enzyme) gene (Rigat, et al., 1990). Three 
independent studies showed that ACE Alu I/D variant is associated with the hypertension 
risk only in men and not in women (Higaki, et al., 2000; O'Donnell, et al., 1998; 
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Stankovic, et al., 2002). Another explanation for the lack of significant association 
between WNK1 AluYb8 insertion and male blood pressure in the HYPEST study could be 
reduced power as this sample includes twice as many women compared to men. 
Interestingly, 597 bp downstream from AluYb8 insertion lies a C/T SNP (rs880054), the 
C allele (frequency 43.8% in British; 36.1% in Japanese) of which has been associated 
with reduced blood pressure (Osada, et al., 2009; Tobin, et al., 2005). Sequence 
comparison of the wild-type WNK1 and the AluYb8-carrying chromosomes revealed that 
the Alu-insertion had probably occurred on rs880054 T-allele carrying gene variant. 
Consistent with the effect of the Alu-insertion, the rs880054 T-allele has been associated 
with increased risk to hypertension. 
Although a majority of Alu elements are considered to be neutral residents of the human 
genome, an inserted copy of an Alu-repeat could interrupt structurally or functionally 
important genomic regions and consequently affect the expression of a locus (Batzer and 
Deininger, 2002; Callinan and Batzer, 2006). Alu elements may alter gene expression 
through modulating alternative splicing, RNA editing, epigenetic regulation and 
translation regulation (Cordaux and Batzer, 2009; Hasler and Strub, 2006). So far, thirty-
three diseases directly caused by novel Alu insertions have been identified (Belancio, et 
al., 2008). Our study using mRNA extracted from human leucocytes indicated a potential 
effect of the presence of the AluYb8 insertion in WNK1 intron 10 on the expressional 
profile of WNK1 alternative transcripts. Splicing is an incompletely understood process 
carried out by large macromolecular complex spliceosome and directed by numerous 
regulatory elements located within exonic and intronic sequence (Black, 2003). The size 
of the WNK1 intron 10 (human wild type 1211 bp) is remarkably increased by the ~300 
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bp AluYb8 insertion (human variant >1500 bp). Thus, we hypothesize that the presence of 
the AluYb8 insertion may disrupt the spatial intronic structure and/or disarrange the 
possible splicing regulatory sequences within WNK intron 10. Consequently, it may 
affect the splicing efficiency of the down-stream exons 11 and 12. As alternative splicing 
tends to be a tissue and developmental stage specific process (Xu Q, et al., 2002), the 
impact of AluYb8 insertion on the expressional profile of WNK1 may vary in different 
tissues. The current study design was limited to addressing the effect of AluYb8 insertion 
on WNK1 expressional profile in leucocytes. Further in vitro and in vivo studies using 
renal tissues would reveal the potential effect of this Alu-insertion on WNK1 expressional 
profile in kidneys, where it plays an important role in contributing to the regulation of ion 
transport.  
In summary, we identified a novel human-specific polymorphic AluYb8 insertion in 
WNK1. This AluYb8 insertion showed significant association with blood pressure and an 
effect on the expressional profile of alternative WNK1 transcripts in leukocytes. 
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Table 1. Phenotypic parameters of HYPEST and CADCZ study subjects  
Parameter 
HYPEST
1 
CADCZ
1 
Cohort Cases Controls Cases Controls 
No. of individuals 
(male/female) 
1211  
(408/803) 
673  
(228/445) 
601 
(162/439) 
296 
(243/53) 
581 
(279/302) 
Age at recruitment (years) 
mean±SD 
44.8 
±12.5 
56.0 
±9.5 
38.9 
±9.0 
55.6 
±6.7 
47.1 
±11.0 
Age at onset of disease (years) 
mean±SD na 
44.0 
±12.7 na 
51.4 
±7.3 NA 
Body mass index (kg/m2) 
mean±SD 
26.7 
 ±4.8 
30.3 
±5.1 
24.6 
±4.3 
28.5 
±4.1 
26.3 
±4.4 
Systolic blood pressure (mmHg) 
mean±SD 
141.0 
±19.0 
161.4 
±20.7 
127.8 
±8.0 
127.4 
±15.8 
137.4 
 ±18.8 
Diastolic blood pressure (mmHg) 
mean±SD 
87.2 
±11.0 
97.5 
±12.6 
80.8 
±6.4 
85.8 
±9.6 
81.2 
±10.1 
Antihypertensive treatment 
(% of subjects) 0.0% 78.5% 0.0% 55.6% 10.8% 
Myocardial infarction 
(% of subjects) 0.0% 11.9 % 0.0% 70.3 % 0.0% 
1
 Recruitment in HYPEST and CADCZ studies is described in Supplementary Text S1 and 
definition of cases/controls of essential hypertension (HYPEST) and coronary artery disease 
(CADCZ) is given in Materials and Methods; na – not applicable 
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Table 2. WNK1 intron 10 AluYb8 allele frequencies in population groups 
Group 
Group 
size 
Allele 
frequency Population composition 
Eastern Europe 150 16.3% Estonians, Czech 
Western Europe 121 14.1% CEPH/Utah families, Basques, Catalans 
Gypsies 50 12.0% Spanish Gypsies 
Volga-Ural 94 17.0% Tatars, Bashkirs 
Eastern Asia 68 16.8% Chinese Han, Koreans 
North Africa 230 16.4% Moroccans, Saharawi, Algerians, Tunisians 
Sub-Saharan Africa 141 4.8% Mandenkalu, Tanzanians, Gabon Bantus, 
Gabon Pygmies 
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Table 3. Association of the WNK1 intron 10 AluYb8 with blood pressure  
HYPEST sample Systolic blood pressure  Diastolic blood pressure  
Subjects N p-value
1 
beta
2
 s.e. p-value
1
 beta
2
 s.e. 
All 1211 0.0126 2.23 0.89 0.0304 1.22 0.56 
women 803 0.0132 2.72 1.10 0.0062 1.84 0.67 
men 408 0.5972 0.78  1.48 0.8672 -0.17 1.03 
1
p-value for linear regression (additive model), age and sex as covariates; p<0.05 in 
bold 
2
effect on blood pressure (mmHg) 
N – sample size; s.e.- standard error 
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Table 4. Association of the WNK1 intron 10 AluYb8 with cardiovascular disease 
Cardiovascular disease
1
 
(study sample) 
Sample size 
case/control 
WNK1 AluYb8  
allele frequency (%) 
Association  
testing
2
  
Cases
1 
Controls p-value 
Essential hypertension (HYPEST sample)   
 all 673/601 17.70 14.51 0.029 
 women 445/439 19.28 14.97 0.016 
 men 228/162 14.63 13.27 0.588 
Coronary artery disease (CADCZ sample)   
 all 296/581 17.23 15.32 0.303 
 women 53/302 18.87 14.90 0.315 
 men 243/279 16.87 15.77 0.624 
1
Definition of essential hypertension and CAD is given in Materials and Methods 
2 
Cochran-Armitage trend test; p<0.05 in bold 
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Figure legends 
Figure 1. Detection of the presence of WNK1 intron 10 AluYb8 insertion in primates.  
Agarose gel (3%) electrophoresis of WNK1 intron 10 PCR products amplified from 
human, chimpanzee, gorilla and orangutan genomic DNAs. In humans, alternative 
genotype carriers are shown: wild-type homozygote without AluYb8 insertion (-/-, 
PCR product 353 bp); heterozygous (A/-) and homozygous (A/A, PCR product 660 
bp) carriers of the insertion. 
 
Figure 2. Box-plot diagram for the distribution of diastolic (DBP) and systolic (SBP) 
blood pressure values in HYPEST sample (all, n=1211; women, n=803; men, n=408). 
The study subjects were sub-grouped based on the carrier status of WNK1 intron 10 
AluYb8. The boxes represent the 25th and 75th percentiles; whiskers are lines 
extending from each end of the box covering the extent of the data on 1.5 x inter-
quartile range. The median value is denoted as the line that bisects the boxes and 
circles represent the outlier values. On each box-plot p-values from linear regression 
testing (additive model, age and sex as covariates) are shown. 
 
Figure 3. Expression of (A) three WNK1 alternative splice-forms in blood leukocytes 
obtained from (B) heterozygous (Alu/-) and (C) homozygous (Alu/Alu) carriers of the 
WNK1 AluYb8 insertion in comparison with the wild-type homozygote without the 
insertion.  
(A) Alternative splicing of WNK1 exons 10-13 is presented schematically according 
to Delaloy et al., 2003. Black numbered boxes and horizontal lines represent exons 
and introns, respectively and dotted lines indicate splicing events. (B, C) Relative 
mRNA quantification of the targeted WNK1 splice-forms in leukocytes was 
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performed with real-time RT-PCR (Taqman assay, HPRT as a reference gene). 
Relative expression of each targeted WNK1 splice-form in subjects with the AluYb8 
insertion (Alu/Alu homozygotes, Alu/– heterozygotes) is shown using the quantity of 
the transcript in wild-type homozygotes (–/–) as a reference value (wt=1). The 
presented relative expression levels represent the mean values of the three study 
subjects within the genotype group (each individual represented by six data-points 
from replicate experiments). Bars represent standard error of the relative expression.  
P-values reflecting the differences between groups were estimated by Wilcoxon rank 
sum test. 
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